Please use this identifier to cite or link to this item: http://scholarbank.nus.edu.sg/handle/10635/118240
Title: Applications of Prolyl Hydroxylase Inhibitors in Tissue Engineering and Regenerative Medicine
Authors: SHAM FONG WAI, ADELINE
Keywords: Angiogenesis, Vascularization, Tissue Engineering, Regenerative Medicine, Biomaterials, Drug Delivery
Issue Date: 31-Mar-2014
Source: SHAM FONG WAI, ADELINE (2014-03-31). Applications of Prolyl Hydroxylase Inhibitors in Tissue Engineering and Regenerative Medicine. ScholarBank@NUS Repository.
Abstract: Clinical applications of tissue engineering are limited mainly to thin or avascular tissues because of inadequate vascularization. In this project, we explored the incorporation of prolyl hydroxylase inhibitors (PHIs) into scaffolds as an alternative vascularization strategy. As a proof of concept, we conjugated the PHI pyridine-2,4-dicarboxylic acid (PDCA) to a gelatin sponge (Gelfoam?) and characterized the resultant constructs. Results showed that PDCA-Gelfoam could stimulate pro-angiogenic signalling in infiltrating cells and accelerate vascular infiltration in rats, demonstrating that our vascularization strategy is viable. As other studies have suggested that PHIs may have applications in bone regeneration, we performed a preliminary study to assess various PHIs? effects on osteoblasts. Results showed that while PHIs could stimulate pro-angiogenic signalling, they also reduced collagen production and had differential effects on mineralization. Our results suggest that both the type of PHI and the duration of treatment are critical determinants of their utility in bone regeneration.
URI: http://scholarbank.nus.edu.sg/handle/10635/118240
Appears in Collections:Ph.D Theses (Open)

Show full item record
Files in This Item:
File Description SizeFormatAccess SettingsVersion 
ShamAFW.pdf4.08 MBAdobe PDF

OPEN

NoneView/Download

Page view(s)

153
checked on Feb 17, 2018

Download(s)

156
checked on Feb 17, 2018

Google ScholarTM

Check


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.